{
  "docId": "019de073-ed1e-723c-a28e-3c378280574e",
  "docSlug": "3439c61eec2c1805f58a361a1d0fbc84",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 36,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Gantt-style visualization to represent the clinical development status of multiple drug candidates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ed1e-723c-a28e-3c378280574e/6",
  "deckHref": "/decks/019de073-ed1e-723c-a28e-3c378280574e",
  "deckJsonHref": "/decks/019de073-ed1e-723c-a28e-3c378280574e.json",
  "deckAnchorHref": "/decks/019de073-ed1e-723c-a28e-3c378280574e#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.28,
        "x": 0.42,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Gantt-style bars representing clinical trial progress for each drug program.",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1622577-99ac-4b3e-bc4d-f81e156d5f05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Note: DMT = N,N-dimethyltryptamine; MDMA = 3,4-Methylenedioxymethamphetamine (1) Perception, Recognize, DemeRx IB, and Kures are all variable interest entities; GABA is a non-consolidated VIE with operational involvement through MSA model; EmpathBio and Viridia are wholly-owned subsidiaries; COMPASS Pathways is a non-controlling equity interests (2) RL-007 compound is (2R, 3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one(L)-(+) tartrate salts (3) Developing COMP360, a formulation of psilocybin, administered with psychological support from specially trained therapists",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db19ef32-d730-4f9c-92b5-1b5462a4d93d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "table",
      "text": "Pipeline table showing Program, Indication, Preclinical, Phase 1, Phase 2, Phase 3, and Affiliate Company columns.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e1b2530-c6ee-46c7-9aec-e7398977b21a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "We will deliver on our strategy through a robust pipeline with drug development programs across several mental health indications with large unmet need",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52ef75b3-fada-43c5-920b-8fd9249f62ce",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "1ae7be56-a3e1-401a-ae82-4e8d04479434",
      "evidence": "The slide features a table with data showing the pipeline programs.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "7bd058f0-a99e-43a1-8cbe-4bf36bf75e8e",
      "evidence": "The slide uses horizontal bars to represent the duration and status of clinical development phases for multiple programs.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}